“Our 2024 outlook places us firmly on track to deliver our 2024-2026 CAGR targets.”

In context

“nge of investors to help us accelerate this critical shift. Thank you. I'll now turn it back to Emmanuel. Emmanuel Babeau: Thank you, Jennifer. I will conclude today's presentation with some key messages. Our excellent IQOS and ZYN volume momentum, best-in-class pricing, positive category mix and stepped-up cost efficiencies put us on track for a strong 2024, with accelerated top-line growth and margin expansion. Following an exceptional and better-than-expected start to the year, we have raised our full year currency-neutral growth forecasts. Critically, we are also focused on delivering performance in dollars. We are taking measures to mitigate currency headwinds through pricing, accelerated manufacturing productivities and judicious resource allocation to prioritize growth investments. Our 2024 outlook places us firmly on track to deliver our 2024-2026 CAGR targets. Beyond 2026, we have further exciting opportunities to grow our smoke-free business as we progress towards our ambition of being substantially smoke-free by 2030. Finally and importantly, our strong growth outlook and highly cash generative business underpins our ability to deleverage while maintaining a steadfast commitment to our progressive dividend policy. We look forward to further rewarding our shareholders as our transformation delivers sustainable growth. Thank you and we are now very happy to answer your questions. Operator: [Operator Instructions] Our first question comes from Matt Smith with Stifel. Your line is now open. Matt Smith: If we start, the first quarter, it was a strong start to the year. You noted a better revenue and margin performance supporting your ability to ra”